Alpha Cognition Inc. $ACOG Shares Sold by MYDA Advisors LLC

MYDA Advisors LLC trimmed its position in shares of Alpha Cognition Inc. (NASDAQ:ACOG) by 54.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,000 shares of the company’s stock after selling 54,000 shares during the period. MYDA Advisors LLC owned approximately 0.29% of Alpha Cognition worth $233,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ACOG. Villere ST Denis J & Co. LLC boosted its position in Alpha Cognition by 201.0% in the 1st quarter. Villere ST Denis J & Co. LLC now owns 71,778 shares of the company’s stock valued at $363,000 after buying an additional 47,928 shares during the last quarter. Salem Investment Counselors Inc. acquired a new position in shares of Alpha Cognition in the first quarter worth about $230,000. Sphera Funds Management LTD. purchased a new position in Alpha Cognition in the fourth quarter valued at about $3,652,000. Bleichroeder LP acquired a new stake in Alpha Cognition during the 4th quarter valued at approximately $1,024,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Alpha Cognition during the 4th quarter worth approximately $2,356,000.

Insider Transactions at Alpha Cognition

In related news, Director Phillip Joseph Mertz sold 27,778 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $9.00, for a total transaction of $250,002.00. Following the completion of the sale, the director owned 22,462 shares of the company’s stock, valued at $202,158. This represents a 55.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert James Wills bought 15,000 shares of the business’s stock in a transaction on Monday, August 18th. The stock was acquired at an average cost of $8.49 per share, for a total transaction of $127,350.00. Following the acquisition, the director directly owned 15,000 shares of the company’s stock, valued at $127,350. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. 14.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on ACOG shares. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alpha Cognition in a research note on Friday, May 16th. Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.00.

Alpha Cognition Trading Up 3.9%

Shares of NASDAQ ACOG opened at $8.24 on Thursday. The company has a market capitalization of $133.16 million, a price-to-earnings ratio of -5.15 and a beta of 2.72. Alpha Cognition Inc. has a twelve month low of $3.75 and a twelve month high of $11.54. The business has a 50 day simple moving average of $9.46 and a 200-day simple moving average of $7.52.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.19). The business had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $2.32 million.

Alpha Cognition Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.